^

Health

Cefangin

, medical expert
Last reviewed: 10.08.2022
Fact-checked
х

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.

We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.

If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

Cefangin is an antibacterial systemic drug from the group of cephalosporins of the 1st generation.

Indications of the cefangina

It is used to eliminate such problems:

  • pathologies affecting the respiratory system and ENT organs (such as sinusitis with bronchitis, and in addition, otitis media or pulmonary inflammation with tonsillitis);
  • infections within the organs of urination, soft tissues, skin, and also bones with joints (such as septic form of arthritis or osteomyelitis).

Release form

The release takes place in capsules, in the amount of 10 pieces inside the blister pack. In the box there are 2 blister plates.

Pharmacodynamics

Cefadroxil is an antibiotic from the group of cephalosporins of the 1st generation taken internally. Has a bactericidal effect.

The drug acts by synthesis with penicillin-binding proteins located inside the cytoplasmic bacterial walls. As a result, the peptidoglycan binding processes inside the cell membranes are suppressed, and then the destruction of the bacterial fission processes, which causes pathogenic organisms to perish.

Cefangin has such antibacterial activity:

  • for gram-positive microorganisms: staphylococci (in this list strains that produce b-lactamases), pneumococci and pyogenic streptococcus;
  • relative to gram-negative bacteria: hemophilic and E. Coli, proteus mirabilis, moraxelli cataralis, salmonella, shigella and neisseria;
  • with respect to anaerobes: bacteroides (except bacteroides fragilis).

Pharmacokinetics

After oral administration, the active element of the drug is almost completely absorbed inside the upper part of the small intestine. The level of bioavailability is 95%. Protein synthesis is rather low - in the range of 15-20%.

The substance quickly passes the distribution inside the fluids with tissues (peritoneal and pericardial fluid, as well as synovia). Penetrates also inside the bile, and at the same time urine with phlegm, and besides inside the pleural effusions and soft tissues with bones. It penetrates through the placenta, and besides it is excreted with the mother's milk.

Excretion of the unchanged component occurs through the kidneys (about 93%) by filtration of glomeruli and secretion of tubules. The half-life with normal renal activity is 1.2-1.5 hours, and in the case of a kidney function up to 20-25 hours.

Dosing and administration

Use Cefangin is necessary regardless of eating, in the amount of 1-2 times / day.

The sizes of portions of drugs, given to adolescents from 12 years (with weight over 40 kg) and adults:

  • infections in the respiratory ducts and ENT systems (such diseases as otitis, tracheobronchitis and sinusitis with tonsillitis) - taking 0.5-1 g of medication (2-4 capsules) twice a day;
  • infectious disorders in the lower parts of the respiratory system (pulmonary inflammation, as well as exacerbated chronic bronchitis) - use of the 1st g of drugs (in the number of 4 capsules) twice a day;
  • diseases affecting the urinary tract - the use of 500-1000 mg of the drug (in the amount of 2-4 capsules) twice a day;
  • infection in the soft tissue with skin - the use of 0.5 g of LS (2 capsules) twice a day;
  • septic form of arthritis, as well as osteomyelitis - taking 1 g of medication (in the amount of 4 capsules) twice a day.

A day is allowed to take no more than 4 g of the drug.

Dosage sizes for children in the 6-12 age group: for all of the above types of diseases, 0.25 grams of medication (1 capsule) should be used twice a day (the capsule must be swallowed whole and prohibited from disclosing it).

This therapy (both in children and adults) should last for 7-10 days. It is also necessary to continue the course for another 48-72 hours after the signs of the disease disappear.

To eliminate infections caused by the action of streptococcus of β-hemolytic type (from category A), therapy with a duration of at least 10 days is necessary. To treat severe forms of infectious diseases (such as osteomyelitis), an even longer course may be required - at least 1-1.5 months.

For individuals with problems in the work of the kidneys (at a CC value less than 50 ml / minute), the size of the portion of the drug is changed taking into account the individual QC level:

  • Values of SC within 25-50 ml / minute - the size of the initial portion is 1 g; maintenance - 0.5 g. Should be taken at intervals of 12 hours;
  • QC values at the level of 10-25 ml / minute - the initial dose is 1 g; maintenance - 0.5 g. Use with intervals of 24 hours;
  • QC level up to 10 ml / minute - the size of the initial dosage is 1000 mg; supporting - 500 mg. Apply at intervals of 36 hours.

Use of the cefangina during pregnancy

It is forbidden to appoint Cefangin to pregnant women. Also, during therapy, you must stop breastfeeding, because the component of cefadroxil is excreted with the mother's milk.

Contraindications

The main contraindications: intolerance to cephalosporin antibiotics, as well as the age of children less than 6 years.

Side effects of the cefangina

The use of the drug may cause some side-effects:

  • infectious or invasive disorders: growth of opportunistic pathogens (fungi) causing thrush, candida-like stomatitis, and vaginal mycosis;
  • violations of hematopoietic function and lymph: occasionally there is leuko-, thrombocyto- or neutropenia, as well as eosinophilia or agranulocytosis (in case of prolonged use). If you cancel the treatment, these violations can be eliminated. A hemolytic form of anemia is noted singly (due to immune disorders);
  • Immune lesions: the appearance of rashes, itching, swelling of the Quincke, hyperthermia or urticaria. In addition, Stevens-Johnson syndrome or erythema multiforme, as well as serum sickness, sometimes develops. Individual anaphylaxis is observed;
  • neurological problems: the sensation of nervousness, excitement or drowsiness is noted singly, and in addition insomnia or dizziness with headaches;
  • problems with the activity of the gastrointestinal tract: dyspeptic symptoms, and in addition nausea, glossitis, diarrhea, vomiting, signs of colitis having a pseudomembranous nature (the appearance of strong gastric spasms and pains, an increase in temperature, and at the same time diarrhea that is watery in nature, with blood);
  • violations in the field of hepatobiliary function: occasionally develops cholestasis or liver failure (due to idiosyncrasy), and in addition a moderate increase in the activity of the transaminase activity of the liver (AST level, as well as ALT) and AF;
  • manifestations from the ODA: arthralgia develops occasionally;
  • problems in the work of urinary organs: occasionally there is an intermediate stage of nephritis;
  • systemic lesions: occasionally there is a fever with a medical origin. There is a feeling of fatigue;
  • indications of laboratory studies: sporadically positive indices of direct, as well as indirect Coombs test are observed sporadically.

trusted-source[1]

Overdose

Signs of intoxication: the appearance of hallucinations, nausea, extrapyramidal disorders of hyperreflexia, sensation of confusion, and in addition the development of a disorder of kidney activity and the state of coma.

To eliminate the overdose, induce vomiting or perform gastric lavage. If required, a procedure for hemodialysis and correction of the water-salt balance is performed. It is also necessary to closely monitor the work of the kidneys.

Interactions with other drugs

Cefangin is forbidden to combine with bacteriostatic antibiotics (such as erythromycin or tetracycline, as well as chloramphenicol or sulfonamides), because this can cause the development of antagonistic manifestations.

It is necessary to abandon the use of drugs in combination with aminoglycosides, colistin, as well as polymiksin type B or with large portions of loop diuretics - due to the fact that these combinations can lead to the appearance of nephrotoxic symptoms.

In the case of combined long-term use of a drug with anticoagulants or drugs that slow down platelet aggregation, in order to avoid the development of complications (the appearance of bleeding) it is required to constantly monitor the indicators of blood uptake.

Admission together with probenecid can lead to a persistent increase in the values of cefadroxil within the bile, as well as blood serum.

The use of powerful diuretics can cause a decrease in cefadroxil levels within the blood.

Cefangin can reduce the severity of the effects of oral contraception.

The drug is synthesized with cholestyramine, because of which the indicators of its bioavailability may decrease.

trusted-source[2], [3]

Storage conditions

Cefangin is required to be kept in a place that is closed from small children. The temperature mark in this case is a maximum of 25 ° C.

trusted-source[4], [5], [6]

Shelf life

Cefangin is allowed to be used for 3 years from the date of manufacture of the drug.

trusted-source[7]

Attention!

To simplify the perception of information, this instruction for use of the drug "Cefangin" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

Translation Disclaimer: For the convenience of users of the iLive portal this article has been translated into the current language, but has not yet been verified by a native speaker who has the necessary qualifications for this. In this regard, we warn you that the translation of this article may be incorrect, may contain lexical, syntactic and grammatical errors.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.